Skip to content
10-Q

Quarterly Report

NORTHWEST BIOTHERAPEUTICS INC NWBO

0001410578-25-001333

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 1.44B sh
Long Term Debt Q1 2025 · Mar 31, 2025 $64.14M
Long Term Debt Q1 2025 · Dec 31, 2024 $62.68M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $2.78M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $2.18M
Current Liabilities Q1 2025 · Mar 31, 2025 $83.06M
Current Liabilities Q1 2025 · Dec 31, 2024 $68.27M
Total Liabilities Q1 2025 · Mar 31, 2025 $112.34M
Total Liabilities Q1 2025 · Dec 31, 2024 $105.71M
Current Assets Q1 2025 · Mar 31, 2025 $4.69M
Current Assets Q1 2025 · Dec 31, 2024 $4.06M
Total Assets Q1 2025 · Mar 31, 2025 $27.51M
Total Assets Q1 2025 · Dec 31, 2024 $26.73M
Shares Diluted Q1 2025 · Mar 31, 2024 1.19M sh
Capex Q1 2025 · Mar 31, 2024 $239K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$12.41M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$73.28M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$65.77M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.02
Eps Basic Q1 2025 · Mar 31, 2024 −$0.02
Sga Expense Q1 2025 · Mar 31, 2024 $8.09M
Rd Expense Q1 2025 · Mar 31, 2024 $7.94M
Net Income Q1 2025 · Mar 31, 2024 −$18.31M
Operating Income Q1 2025 · Mar 31, 2024 −$15.74M
Revenue Q1 2025 · Mar 31, 2024 $284K